2025. KT-621, an Oral, Once Daily, Targeted STAT6 Degrader: First-in-Human Phase 1a Safety, Pharmacokinetics, Pharmacodynamics and Th2 Biomarker Effects. SKIN The Journal of Cutaneous Medicine. 9, 6 (Nov. 2025), s712. DOI:https://doi.org/10.25251/t4cqj323.